Our findings suggest that BRAF gene inhibitors may be effective in slowing down the progression of BRAF-positive LCH, and that standard drugs can also demonstrate significant efficacy when administered according to a well-planned treatment regimen. This evidence concerns the gene BRAF and Langerhans cell histiocytosis.